- Home
- NTRB vs ANVS Comparison
NTRB vs ANVS Comparison
Compare NTRB & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- ANVS
- Stock Information
- Founded
- NTRB 2016
- ANVS 2008
- Country
- NTRB United States
- ANVS United States
- Employees
- NTRB N/A
- ANVS N/A
- Industry
- NTRB Industrial Specialties
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- ANVS Health Care
- Exchange
- NTRB Nasdaq
- ANVS Nasdaq
- Market Cap
- NTRB 71.8M
- ANVS 55.5M
- IPO Year
- NTRB N/A
- ANVS 2020
- Fundamental
- Price
- NTRB $7.00
- ANVS $2.48
- Analyst Decision
- NTRB Buy
- ANVS Strong Buy
- Analyst Count
- NTRB 1
- ANVS 4
- Target Price
- NTRB $13.00
- ANVS $17.33
- AVG Volume (30 Days)
- NTRB 33.0K
- ANVS 218.3K
- Earning Date
- NTRB 09-09-2025
- ANVS 11-07-2025
- Dividend Yield
- NTRB N/A
- ANVS N/A
- EPS Growth
- NTRB N/A
- ANVS N/A
- EPS
- NTRB N/A
- ANVS N/A
- Revenue
- NTRB $2,578,059.00
- ANVS N/A
- Revenue This Year
- NTRB $560.75
- ANVS N/A
- Revenue Next Year
- NTRB $588.39
- ANVS N/A
- P/E Ratio
- NTRB N/A
- ANVS N/A
- Revenue Growth
- NTRB 42.92
- ANVS N/A
- 52 Week Low
- NTRB $2.98
- ANVS $1.11
- 52 Week High
- NTRB $9.42
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- NTRB 56.92
- ANVS 52.16
- Support Level
- NTRB $5.85
- ANVS $2.26
- Resistance Level
- NTRB $7.48
- ANVS $2.51
- Average True Range (ATR)
- NTRB 0.43
- ANVS 0.12
- MACD
- NTRB 0.11
- ANVS 0.02
- Stochastic Oscillator
- NTRB 71.29
- ANVS 87.10
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.